Leerink Partners: 'We expect MDT to trade higher tomorrow'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Leerink Partners: 'We expect MDT to trade higher tomorrow'
July 11, 2025 12:26 PM EDT
Goldman Sachs analyst David Roman reiterated a Sell rating and $78.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "On Thursday, July 10th, the Centers for Medicare and Medicaid Services (CMS) released a proposed Decision Memo to cover Renal Denervation (RDN) -- either radiofrequency (Medtronic) or ultrasound-based (Recor Medical, a subsidiary of... More
July 11, 2025 8:22 AM EDT
Raymond James analyst Jayson Bedford reiterated a Market Perform rating on Medtronic, Inc. (NYSE: MDT).
The analyst comments "CMS released its proposed National Coverage Determination (NCD) for Renal Denervation (RDN) last night (here). An NCD provides necessary scope around clinical eligibility for reimbursement purposes. The timeline was expected (on/before July 11). This document triggers another 30-day comment period, culminating with a final NCD expected to be published on/around October 8, 2025. Punchline: We believe the document reads well with no unexpected restrictions. CMSs inclusion threshold of 140 mmHg ambulatory blood pressure (which we believe equates... More
July 11, 2025 6:01 AM EDT
BTIG analyst Sean Lavin reiterated a Neutral rating and {REMOVEPT} price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "WHAT YOU SHOULD KNOW: Announced today, CMS provided its proposed National Coverage Decision (NCD) for Renal Denervation (RDN). As anticipated, CMS is proposing to cover RDN for uncontrolled hypertension. Even though this was anticipated we think it's still a win for Medtronic (MDT, Neutral) who has been preparing sites for coverage with the launch of Symplicity Spyral as it ramps up outpatient hypertension programs. We run through the criteria included in... More
July 11, 2025 5:57 AM EDT
Evercore Comments on Medtronic (NYSE: MDT)
The analyst comments "Today, CMS published in proposed NCD decision memo for Renal Denervation (RDN). Here are the details: Coverage Criteria: CMS proposed coverage for RF and ultrasound renal denervation (RDN) for pts with >140/90mm Hg and uncontrolled hypertension (rHTN) under coverage with evidence development (CED) see Fig 1. CED process notes study must incl. >1 BP endpoints (e.g. ASBP) and adverse events (e.g. mortality/worsening renal... More
